Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of PF-06650833 in Healthy Subjects
NCT03308110Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zimlovisertib in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve Last. Started Sep 2017; status: completed.
02
Drugs
zimlovisertib
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03308110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308110.